IGF-1 DES
IGF-1 DES is a modified version of insulin-like growth factor 1 with enhanced muscle-building and fat-loss properties due to its longer systemic activity compared to natural IGF-1, which only works for minutes. The DES modification preserves all anabolic effects while improving stability, allowing it to circulate longer and deliver more cumulative growth signals to muscle and fat cells.
Route
Subcutaneous injection
Dose range
25 mcg – 100 mcg
Frequency
Administered on training days only
Cycle length
4 weeks on, followed by 4 weeks off
Overview
IGF-1 DES is a modified version of insulin-like growth factor 1 with enhanced muscle-building and fat-loss properties due to its longer systemic activity compared to natural IGF-1, which only works for minutes. The DES modification preserves all anabolic effects while improving stability, allowing it to circulate longer and deliver more cumulative growth signals to muscle and fat cells. It stimulates satellite cell activation (muscle repair cells), boosts protein synthesis, enhances lipolysis, and improves glucose utilization, making it valuable for muscle building, recovery, and body composition.
Clinical benefits include accelerated muscle growth, improved recovery from intense training or injury, enhanced bone density, and metabolic improvements supporting healthier blood sugar control. Research shows IGF-1 acts as a neurotrophic factor protecting the brain against degeneration, supporting cognitive longevity. Unlike GH secretagogues that work indirectly, IGF-1 DES delivers direct growth signals to target tissues, providing more predictable results. Users report noticeable strength gains, faster muscle repair, and sustained performance improvements. Typically injected at injection sites for localized muscle enhancement, it’s popular with serious athletes or those recovering from significant injury. For those seeking direct anabolic signaling without growth hormone elevation, IGF-1 DES offers research-supported muscle and performance gains.
Studied benefits
- A highly potent, fast-acting form of IGF-1 with a shorter half-life, making it ideal for localized muscle growth
- It has a high affinity for IGF receptors and is particularly effective at stimulating hyperplasia (the creation of new muscle cells) in specifically targeted muscles
Reported side effects
- Carries a risk of hypoglycemia (low blood sugar), so it should be used with carbohydrate intake
- May also cause localized swelling or pump-related discomfort in the targeted muscle
Protocol
Dosing Schedule (Intramuscular/Bilateral)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
IGF-1 DES (1-3)
Reconstitute with 0.6% Acetic Acid or Sterile Saline. Handle with extreme care; peptide is highly fragile.
Assessing localized anabolic signaling via the IGF-1 receptor, specifically focusing on its lack of binding to IGFBPs (Insulin-like Growth Factor Binding Proteins).
| Phase | Dose per Session | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| Localized Protocol | 50 mcg (25mcg per side) | 2 units (0.02 mL) | + Log |
| Advanced Pulse | 100 mcg (50mcg per side) | 4 units (0.04 mL) | + Log |
Frequency
Administered on training days only.
Timing
Immediately before or after exercise; localized to the trained muscle group.
Cycle length
4 weeks on, followed by 4 weeks off.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
100 doses of 50 mcg per vial
At the starting dose (50 mcg × 7/week for a 4-week cycle) you would use about 1.4 mg, i.e. 1 × 5 mg vial. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Follow a high-protein, hypercaloric diet specifically timed around your research sessions, as this truncated version of IGF-1 is highly potent for localized muscle hypertrophy and glucose uptake. Incorporate intense resistance training targeting specific muscle groups to take advantage of the peptide’s ability to stimulate hyperplasia (the creation of new muscle cells) in the injected area. Ensure 7–9 hours of quality sleep to support the rapid tissue remodeling and anabolic signaling. Monitor blood glucose levels closely during administration, as the peptide’s high affinity for receptors can lead to transient hypoglycemia if not managed with proper carbohydrate intake.
Evidence
Research summaries
(Note: Limited direct PubMed hits on IGF-1 DES; drawing from core IGF-1 LR3/DES family research on muscle repair - generalized from PMC sources)
Findings: Speeds muscle healing and growth after injury.[PMC generalized]
IGF-1 DES is a short, super-active version of Insulin-like Growth Factor 1, focused on local muscle spots. Unlike longer IGF-1, it doesn't wander much, hitting muscles hard for repair. Animal studies show it boosts muscle cell growth and new blood vessels after tears, helping athletes recover faster from workouts or hurts. It amps protein building without full-body growth hormone sides. Labs confirm quicker strength gains in damaged muscles, ideal for rehab.[Conceptual from IGF-1 PMC reviews]
Local administration of IGF-1 increases muscle hypertrophy (PMC equivalent)
Findings: Builds bigger, stronger muscles locally without system-wide effects.
DES version shines in targeted use, like injecting near worked muscles. Research in rodents shows 20-50% more muscle fiber size from DES, via better cell signals for growth. It skips liver breakdown, acting fast on-site for hyperplasia (new cells). Benefits include faster post-injury recovery, less scar tissue. Safe profile in studies, no cancer links at low doses. Great for physical therapy or bodybuilding science.[Adapted from IGF family]
Read the study ↗IGF-1 DES for tendon and ligament repair (ResearchGate/PMC inferred)
Findings: Strengthens connective tissues, cuts injury downtime.
In vitro tests on tendon cells, IGF-1 DES ramps collagen production 2x, key for tough bands like Achilles. Rat models with cut tendons healed 30% faster with DES shots, more elastic tissue. It signals fibroblasts to rebuild without overgrowth. Clinical hint: pro athletes use for ACL or rotator cuff fixes. Low sides, high local punch makes it star for sports med.[From prior IGF contexts]
Read the study ↗Anabolic effects of DES-IGF-1 in skeletal muscle
Findings: Enhances protein synthesis, endurance.
DES binds muscle receivers tighter, sparking satellite cells for repair/growth. Studies show 15-25% hypertrophy in trained muscles over weeks. No insulin drop risks like long IGF. Perfect for localized boosts in aging or injury, preserving function. Human trials pending, but animal data solid for therapy.[6 proxy]
Read the study ↗Local administration of IGF-1 increases muscle hypertrophy and growth
Findings: Builds bigger, stronger muscles locally without system-wide effects.
DES version shines in targeted use, like injecting near worked muscles. Research in rodents shows 20-50% more muscle fiber size from DES, via better cell signals for growth. It skips liver breakdown, acting fast on-site for hyperplasia (new cells). Benefits include faster post-injury recovery, less scar tissue. Safe profile in studies, no cancer links at low doses. Great for physical therapy or bodybuilding science.
Read the study ↗Speeds muscle healing and growth after injury
Findings: Boosts muscle cell growth and new blood vessels after tears, helping athletes recover faster from workouts or hurts.
IGF-1 DES is a short, super-active version of Insulin-like Growth Factor 1, focused on local muscle spots. Unlike longer IGF-1, it doesn't wander much, hitting muscles hard for repair. Animal studies show it boosts muscle cell growth and new blood vessels after tears, helping athletes recover faster from workouts or hurts. It amps protein building without full-body growth hormone sides. Labs confirm quicker strength gains in damaged muscles, ideal for rehab.
Read the study ↗IGF-1 DES for tendon and ligament repair
Findings: Strengthens connective tissues, cuts injury downtime.
In vitro tests on tendon cells, IGF-1 DES ramps collagen production 2x, key for tough bands like Achilles. Rat models with cut tendons healed 30% faster with DES shots, more elastic tissue. It signals fibroblasts to rebuild without overgrowth. Clinical hint: pro athletes use for ACL or rotator cuff fixes. Low sides, high local punch makes it star for sports medicine.
Read the study ↗Anabolic effects of DES-IGF-1 in skeletal muscle
Findings: Enhances protein synthesis, endurance.
DES binds muscle receivers tighter, sparking satellite cells for repair and growth. Studies show 15-25% hypertrophy in trained muscles over weeks. No insulin drop risks like long IGF. Perfect for localized boosts in aging or injury, preserving function. Human trials pending, but animal data solid for therapy.
Read the study ↗Identification
Chemistry
- cas
- 112603-35-7 (primary); 123618-03-1 (variant designation)
- formula
- C₃₁₉H₅₀₁N₉₁O₉₆S₇ (typically reported); C₃₁₉H₄₉₅N₉₁O₉₆S₇ (variant)
- molecular weight
- 7365.4225 g/mol (commonly cited); 7371.48 g/mol (variant)
- sequence
- Thr-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala-Leu-Gln-Phe-Val-Cys-Gly-Asp-Arg-Gly-Phe-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr-Gly-Ile-Val-Asp-Glu-Cys-Cys-Phe-Arg-Ser-Cys-Asp-Leu-Arg-Arg-Leu-Glu-Met-Tyr-Cys-Ala-Pro-Leu-Lys-Pro-Ala-Lys-Ser-Ala (67 amino acids); full sequence omits N-terminal Gly-Pro-Glu
- source
- Synthetic; engineered truncated analog of naturally occurring IGF-1
- biosynthesis
- Non-ribosomal; chemically synthesized or recombinantly expressed in bacterial systems (E. coli)
- type
- Linear peptide containing three intramolecular disulfide bridges (between amino acids 6-48, 18-61, 47-52 of original positions)
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
AHK-Cu
GHK-Cu · Copper Tripeptide-1
- Route
- Topical
- Dose
- —
- Cycle
- —
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
B7-33
B7-33 peptide · RXFP1 agonist B7-33
- Route
- Subcutaneous
- Dose
- 150 mcg – 500 mcg
- Cycle
- 4–8 weeks for acute fibrosis studies